

Investor News

Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com

Bayer to early redeem EUR 1.3 billion bond issued in 2005

Leverkusen, April 15, 2015 – Bayer AG plans to early redeem a EUR 1.3 billion bond. The first opportunity to repay the subordinated bond with a 5 percent coupon and a 100year maturity issued in 2005 (ISIN XS0225369403) arises on July 29, 2015. Bayer has decided to utilize this repayment right. The company will arrange for publication of a formal investor notification in the newspaper *Luxemburger Wort* or via the clearing system in June 2015 in accordance with the bond conditions.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. For more information, go to www.bayer.com.

Bayer AG, Investor Relations contacts: Dr. Alexander Rosar (+49-214-30-81013) Dr. Jürgen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Judith Nestmann (+49-214-30-66836) Constance Spitzer (+49-214-30-33021) Dr. Olaf Weber (+49-214-30-33567)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at <u>www.bayer.com</u>. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.